v3.23.2
NET LOSS PER SHARE (Tables)
 6 Months Ended
Jun. 30, 2023
Earnings Per Share [Abstract]  
Schedule of Reconciliation of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders The following is a reconciliation of basic and diluted net loss per share:
Three Months EndedSix Months Ended
June 30,June 30,
2023202220232022
Net loss$(2,886)$(333)$(9,692)$(9,433)
Weighted average number of shares - basic and diluted22,704,723 19,792,286 22,587,022 19,693,216 
Net loss per share - basic and diluted$(0.13)$(0.02)$(0.43)$(0.48)
Schedule of Antidilutive Shares Excluded from the Calculation of Diluted Net Loss Per Share The following contingently issuable equity shares were excluded from the calculation of diluted net loss per share because their effect would have been anti-dilutive for all periods presented:
Six Months Ended June 30,
20232022
Restricted stock580,162 433,093 
Stock options3,556 5,298 
Total shares583,718 438,391 
The contingently issuable shares in the table above do not include shares of our common stock associated with our recent acquisitions of Pega Medical, ApiFix or MedTech. See Note 3 for additional information regarding future equity issuances under each of these acquisitions.